EYEPOINT PHARMACEUTICALS, INC Revenue 2006-2021 | EYPT

EYEPOINT PHARMACEUTICALS, INC revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
EYEPOINT PHARMACEUTICALS, INC Annual Revenue
(Millions of US $)
2020 $34
2019 $20
2018 $
2018 $3
2017 $8
2016 $2
2015 $27
2014 $3
2013 $2
2012 $4
2011 $5
2010 $23
2009 $12
2008 $3
2007 $
2007 $2
2006 $
2006 $1
2005 $1
EYEPOINT PHARMACEUTICALS, INC Quarterly Revenue
(Millions of US $)
2021-06-30 $9
2021-03-31 $7
2020-12-31 $7
2020-09-30 $16
2020-06-30 $4
2020-03-31 $7
2019-12-31 $9
2019-09-30 $3
2019-06-30 $7
2019-03-31 $2
2018-12-31
2018-09-30 $0
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $0
2017-06-30
2017-03-31 $1
2016-12-31 $6
2016-09-30 $0
2016-06-30
2016-03-31 $0
2015-12-31 $1
2015-09-30 $0
2015-06-30
2015-03-31 $0
2014-12-31 $1
2014-09-30 $25
2014-06-30
2014-03-31 $2
2013-12-31 $1
2013-09-30 $1
2013-06-30
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30
2012-03-31 $1
2011-12-31 $1
2011-09-30 $2
2011-06-30
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30
2010-03-31 $1
2009-12-31 $3
2009-09-30 $3
2009-06-30
2009-03-31 $3
2008-12-31 $3
2008-09-30 $3
2008-06-30
2008-03-31 $1
2007-12-31 $0
2007-09-30 $0
2007-06-30
2007-03-31 $0
2006-12-31 $1
2006-09-30 $1
2006-06-30
2005-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.337B $0.034B
EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29